J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Executive Administrative Assistant

Full-TimePosted on 10/23/2026Deadline 10/30/26
$78.1k - $125.2k
Senior, Expert
Associate's
West Chester, PA, USA+3 moreMore locations: New Brunswick, NJ, USA | Raynham, MA, USA | Palm Beach Gardens, FL, USA
HybridHybrid role; work from one of the five listed locations.
Administrative & Executive AssistanceExecutive Support

About the job

Requirements
  • An associate’s degree is required.
  • A minimum of 8 years of experience in executive coordination or senior administrative support within complex, matrixed organizations, including proven support of VP- or SVP-level leaders, is required.
  • Experience leveraging AI tools to enhance productivity and workflow efficiency is required.
  • Strong proficiency in Concur Travel & Expense, Microsoft Suite, Excel, and PowerPoint is required.
  • Advanced calendar, meeting, and event management experience is required.
  • Exceptional written and verbal communication skills are required.
  • High judgment, discretion, and emotional intelligence are required.
  • Ability to synthesize information, anticipate needs, and operate independently is required.
  • Comfort with ambiguity, shifting priorities, and incomplete inputs is required.
  • Strong organizational discipline paired with enterprise-level thinking is required.
Responsibilities
  • Act as a trusted thought partner to SVP/VP leaders, proactively managing administrative and operational demands to support enterprise strategy and leadership priorities.
  • Operate with a CEO-office mindset, anticipating downstream impacts, sequencing, and trade-offs across business, governance, and external commitments.
  • Exercise independent judgment in managing time, access, and information flow, escalating when value-adding or risk-mitigating.
  • Provide stability, clarity, and momentum in complex, fast-moving environments.
  • Manage complex, high-stakes calendars across global time zones, balancing governance, leadership availability, and external visibility.
  • Serve as an effective gatekeeper for scheduling and access.
  • Own the annual executive cadence, anticipating leadership meetings, board-adjacent activity, talent reviews, enterprise forums, conferences, and external engagements.
  • Proactively optimize calendars to protect focus time and align time investment with enterprise priorities.
  • Coordinate internal and external meetings, ensuring executives are prepared with the appropriate materials, context, and stakeholders.
  • Manage end-to-end meeting logistics, including agendas, pre-reads, and executive-ready presentation materials.
  • Partner with leaders and other executive assistants or coordinators to align agendas and sequencing for complex, multi-leader forums.
  • Track and coordinate follow-ups, actions, and decisions to ensure accountability and momentum.
  • Manage executive email and correspondence, filtering routine messages and surfacing critical issues.
  • Draft responses and communications that reflect executive voice, intent, and priorities.
  • Serve as a primary point of contact for SVP/VP leaders, tracking action items and follow-ups.
  • Act as a professional interface with senior leaders, internal teams, external partners, and vendors.
  • Coordinate internal and external communications and initiatives on behalf of SVP/VP leaders.
  • Oversee office operations, including supplies, services, purchasing, and vendor coordination.
  • Maintain efficient administrative processes and provide backup support across the administrative team as needed.
  • Support leadership initiatives and special projects based on priorities and capacity.
  • Assist with offsites, visitor management, compliance tracking, committee coordination, and contract or payment processes.
  • Support internal communities, including the Credo Committee, Culture Team, WiSTEM, and employee resource groups, through coordination and logistics.
  • Independently manage or contribute to operational projects tied to leadership effectiveness or transformation.
  • Maintain organized electronic and physical filing systems, and record and distribute meeting minutes.
  • Support onboarding by coordinating materials, access, and logistics.
  • Coordinate travel, lodging, and transportation for senior executives.
  • Process and reconcile expenses in compliance with policy.
  • Plan and execute meetings and events, including logistics, audiovisual arrangements, space setup, and catering.
  • Assist with budget tracking as required.
  • Continuously improve administrative and departmental workflows.
  • Handle sensitive and business-critical information with discretion and professionalism.
  • Ensure operational reliability so leaders can operate effectively without administrative distraction.
  • Liaise with internal teams, external partners, and vendors to ensure smooth operations.
  • Enable cross-functional collaboration through clear communication and follow-through.
Desired Qualifications
  • Preferred skills include administrative support, business writing, communication, customer centricity, data capturing, diary management, document management, execution focus, Microsoft Office, office administration, organizational knowledge, organizing, presentation development, problem solving, professional ethics, travel planning, and typing.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.